Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States.
Curr Pharm Des. 2018;24(4):414-426. doi: 10.2174/1381612824666171227211623.
Thrombolytic therapy kick-started the era of modern cardiology but in the last few decades it has been largely supplanted by primary percutaneous coronary intervention (PCI) as the go-to treatment for acute myocardial infarction. However, these agents remain important for vast populations without access to primary PCI and acute ischemic stroke. More innovative uses have recently come up for the treatment of a variety of conditions. This article summarizes the history, evidence base and current use of thrombolytics in cardiovascular disease.
溶栓治疗开创了现代心脏病学的时代，但在过去几十年中，它已在很大程度上被经皮冠状动脉介入治疗（PCI）所取代，成为急性心肌梗死的首选治疗方法。然而，对于无法进行 PCI 和急性缺血性脑卒中的广大人群来说，这些药物仍然非常重要。最近，溶栓治疗在各种疾病的治疗方面有了更多创新应用。本文总结了溶栓治疗在心血管疾病中的历史、证据基础和当前应用。
